Vir Biotechnology (NYSE:VIR) Expected to Announce Earnings of -$7.40 Per Share

Wall Street analysts expect that Vir Biotechnology (NYSE:VIR) will report earnings of ($7.40) per share for the current quarter, according to Zacks. Zero analysts have provided estimates for Vir Biotechnology’s earnings. The business is scheduled to announce its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Vir Biotechnology will report full-year earnings of ($3.63) per share for the current financial year, with EPS estimates ranging from ($5.25) to ($2.01). For the next financial year, analysts expect that the firm will post earnings of ($1.96) per share, with EPS estimates ranging from ($2.00) to ($1.91). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that follow Vir Biotechnology.

VIR has been the topic of a number of recent analyst reports. Goldman Sachs Group initiated coverage on shares of Vir Biotechnology in a research note on Tuesday, November 5th. They set a “buy” rating and a $37.00 price target on the stock. Cowen initiated coverage on shares of Vir Biotechnology in a research note on Tuesday, November 5th. They set an “outperform” rating on the stock. JPMorgan Chase & Co. initiated coverage on shares of Vir Biotechnology in a research note on Tuesday, November 5th. They set an “overweight” rating and a $25.00 price target on the stock. Robert W. Baird initiated coverage on shares of Vir Biotechnology in a research note on Wednesday. They set a “neutral” rating on the stock. Finally, Barclays initiated coverage on shares of Vir Biotechnology in a research note on Tuesday, November 5th. They set an “overweight” rating and a $25.00 price target on the stock. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Vir Biotechnology presently has a consensus rating of “Buy” and an average target price of $29.00.

Vir Biotechnology stock traded down $0.08 during mid-day trading on Friday, reaching $13.02. 109,300 shares of the company traded hands, compared to its average volume of 192,532. Vir Biotechnology has a fifty-two week low of $12.72 and a fifty-two week high of $16.50.

In other Vir Biotechnology news, insider Abu Dhabi Investment Authority acquired 1,000,000 shares of the business’s stock in a transaction dated Wednesday, October 16th. The shares were purchased at an average price of $14.41 per share, for a total transaction of $14,410,000.00. Also, major shareholder Endurance (Cayman) Ltd Svf acquired 950,000 shares of the business’s stock in a transaction dated Wednesday, October 16th. The stock was acquired at an average price of $14.22 per share, for a total transaction of $13,509,000.00.

About Vir Biotechnology

Vir Biotechnology, Inc, a clinical-stage immunology company, develops therapeutic products for the treatment and prevention of serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus, and VIR-2020 for the prevention of tuberculosis.

Featured Story: Key terms to understand channel trading

Get a free copy of the Zacks research report on Vir Biotechnology (VIR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.